The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Clarithromycin Therapy for Bacteremic Mycobacterium avium Complex Disease: A Randomized, Double-Blind, Dose-Ranging Study in Patients with AIDS

Richard E. Chaisson, MD; Constance A. Benson, MD; Michael P. Dube, MD; Leonid B. Heifets, MD; Joyce A. Korvick, MD; Saralyn Elkin, BSN; Ted Smith, MD; J. Carl Craft, MD; Fred R. Sattler, MD, AIDS Clinical Trials Group Protocol 157 Study Team.
[+] Article, Author, and Disclosure Information

From the Johns Hopkins University School of Medicine, Baltimore, Maryland; Rush Medical College, Chicago, Illinois; University of Southern California-Los Angeles County Medical Center, Los Angeles, California; National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado; Abbott Laboratories, Abbott Park, Illinois; the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; BioPharm, Inc., Philadelphia, Pennsylvania. For members of the AIDS Clinical Trials Study Team, see the Appendix. Requests for Reprints: Richard E. Chaisson, MD, AIDS Service, The Johns Hopkins University, 600 North Wolfe Street, Carnegie 292, Baltimore, MD 21287-6220. Grant Support: By grant 5M01RR00722 and the AIDS Clinical Trials Group.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1994;121(12):905-911. doi:10.7326/0003-4819-121-12-199412150-00001
Text Size: A A A

Objective: To determine the antimicrobial activity and tolerability of clarithromycin for treating bacteremic Mycobacterium avium complex disease in patients with the acquired immunodeficiency syndrome (AIDS).

Design: A randomized, double-blind, dose-ranging study.

Setting: Outpatient clinics.

Patients: 154 patients with human immunodeficiency virus (HIV) infection and blood cultures positive for M. avium complex who had symptomatic disease.

Interventions: Random assignment to clarithromycin at dosages of 500 mg, 1000 mg, or 2000 mg twice daily for 12 weeks.

Main Outcome Measure: Median number of colony-forming units of M. avium complex per milliliter of blood.

Results: Clarithromycin decreased mycobacterial CFUs from 2.7 to 2.8 log 10/mL of blood at baseline to less than 0 log 10/mL during follow-up (P < 0.0001). After 2 weeks, patients receiving 500 mg twice daily were less likely to be culture negative than were patients receiving 1000 or 2000 mg twice daily (11% compared with 33% or 29%; P = 0.08). At 6 weeks, the median number of CFUs of M. avium complex/mL of blood was 0 or 1 for all three groups. Clarithromycin-resistant isolates of M. avium complex developed in 46% of patients at a median of 16 weeks. Median survival was longer in patients assigned to 500 mg twice daily (median, 249 days) than in patients assigned to 1000 mg or 2000 mg. Death in the first 12 weeks was lowest in the 500-mg group (P = 0.007).

Conclusions: Clarithromycin therapy acutely decreased M. avium complex bacteremia in patients with HIV infection by more than 99%. Clarithromycin, 500 mg twice daily, was well tolerated and associated with better survival. Emergence of clarithromycin-resistant organisms was an important problem.


Grahic Jump Location
Figure 1.
Kaplan-Meier estimates of the probability of blood culture positivity for M. avium-complex during treatment by dose of clarithromycin.P

Patients received 500 mg, 1000 mg, or 2000 mg twice daily. Rows at the bottom represent the number of uncensored patients at specific time points by dose. The overall difference among the three treatment groups was = 0.04.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Survival estimates for patients by dose of clarithromycin.PPP

Patients received 500 mg, 1000 mg, or 2000 mg twice daily. Rows at the bottom represent the number of uncensored patients at specific time points by dose. The overall difference among the three treatment groups was = 0.08. The difference between the 500-mg and 1000-mg groups was = 0.20. The difference between the 500-mg and 2000-mg groups was = 0.02.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.